UNSPSC 51283004: Clindamycin palmitate

This classification denotes a lincosamide antibiotic with the molecular formula C34H63ClN2O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C501Z28AFG, chemically known as methyl (2s-trans)-7-chloro-6,7,8-trideoxy-6-(((1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-l-threo-alpha-d-galacto-octopyranoside, monopalmitate (ester) but more generally known as clindamycin palmitate, which bears US NIH Compound Identifier 83855.

Most nations, for tariff and trade purposes, schedule clindamycin palmitate under HS 29419000 and SITC 54139. As of Q4 2014, CLINDAMYCIN PALMITATE remains US FDA's Preferred Term for this commodity. SMILES: CCCCCCCCCCCCCCCC(=O)O[C@@H]1[C@H]([C@H]([C@H](O[C@@H]1SC)[C@@H]([C@H](C)CL)NC(=O)[C@@H]2C[C@H](CN2C)CCC)O)O.

UNSPSC 51283004 Clindamycin palmitate is a Commodity code that captures pharmaceutical supply procurement by state and local governments, though recent solicitation activity under this code shows significant scope divergence — the opportunities posted are purchasing broader pharmaceutical categories, emergency medical supplies, and direct-to-manufacturer pharmacy programs rather than the specific antibiotic clindamycin palmitate itself. State and local issuing bodies soliciting under or near this code include county health departments, state health and human services agencies, municipal fire and rescue divisions, and cooperative purchasing alliances. The actual work being solicited spans generic multi-source pharmaceuticals and OTC products through established wholesale channels, emergency response medical and first aid supplies for fire rescue operations, direct-to-manufacturer prescription fulfillment programs, and naloxone and drug deactivation systems for community health initiatives. Issuing bodies range from small municipal departments to statewide cooperative purchasing vehicles serving multiple jurisdictions.

Recent activity concentrates in Florida, Texas, and Minnesota. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP posted January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon, requiring manufacturers to supply through three authorized wholesalers with pricing effective July 1, 2026. The City of Tampa's Purchasing Department solicited sealed bids (26P00145) posted March 25, 2026 (due March 13, 2026) for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, with an estimated contract value of $700,000 and a 5 percent bid discount available for certified Small Local Business Enterprises. Seminole County, Florida released an IFB (IFB60459723LAS) posted June 30, 2026 for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries. The Texas Health and Human Services Commission issued an RFI (HHS0017013) posted April 3, 2026 to explore vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program as a market-intelligence precursor to formal solicitation.